Search
Repaglinide
go.drugbank.com/drugs/DB00912ApprovedInvestigationalThe average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control
Mixtures: PAREGLIN 1 MG/500 MG FILM KAPLI TABLET, 90 ADET, REPAMEF 1/1000 MG EFERVESAN TABLET, 30 ADETCategories: Heterocyclic Compounds, 1-RingPotassium voltage-gated channel subfamily A member 10
go.drugbank.com/bio_entities/BE0004720TargetHumansVoltage-gated potassium ion channel that mediates K(+) permeability of excitable membranes. When opened in response to the voltage difference across the membrane, KCNA10 channel selectively allows the flow of potassium ions across the me...
Polypeptides: Potassium voltage-gated channel subfamily A member 10Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational[A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®
Products: XGEVA® 120 MG/1.7 ML, XGEVA Solution for Injection 120 mg/vialPhenoxybenzamine
go.drugbank.com/drugs/DB00925ApprovedInvestigationalAn alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
Categories: Peripheral alpha-1 blockers, Adrenergic alpha-1 Receptor AntagonistsProducts: Dibenzyran 10 mg KapselnNADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10
go.drugbank.com/bio_entities/BE0000245TargetHumansAccessory subunit that is involved in the functional assembly of the mitochondrial respiratory chain complex I. Complex I has an NADH dehydrogenase activity with ubiquinone as an immediate electron acceptor and mediates the transfer of e...
Polypeptides: NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10ATP-binding cassette sub-family C member 10
go.drugbank.com/bio_entities/BE0003651TransporterHumansATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds, and xenobiotics from cells. Lipophilic anion transporter that mediates ATP-dependent transport of glucuronide conjugates s...
Polypeptides: ATP-binding cassette sub-family C member 10Glyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigational[A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120]
Mixtures: DUPLAX 500 MG/5 MG FILM KAPLI TABLET, 120 ADET, DUPLAX 500 MG/5 MG FILM KAPLI TABLET, 180 ADETSynonyms: 1-((p-(2-(5-chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylureaLabetalol
go.drugbank.com/drugs/DB00598ApprovedInvestigational[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Categories: Peripheral alpha-1 blockers, Adrenergic alpha-1 Receptor AntagonistsSynonyms: 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide, 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcoholRomosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalIn a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months … Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921].
Products: EVENITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 105 MG/1.17 ML, EVENİTY 105 MG/1,17 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADETPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigational[F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1. … It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: KEYTRUDA® 100 MG, KEYTRUDA 100 MG/4 ML IV INFUZYONLUK COZELTI İÇEREN FLAKON, 1 ADET